# Nuclide record f-18-fdg-brain (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/f-18-fdg-brain/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "f-18-fdg-brain" ;
  schema:name "Fludeoxyglucose F-18 (brain metabolism)"@en ;
  schema:alternateName "FDG-PET brain"@en, "18F-FDG"@en ;
  schema:description "The standard PET tracer for measuring how the brain is using energy; a pattern of low activity in particular brain regions can help doctors work out which type of dementia a patient has."@en ;
  schema:url <https://nuclide.cc/drugs/f-18-fdg-brain/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r24ncd.pdf>, <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53134> ;
  nuclide:status "approved" ;
  nuclide:tag "FDG PET", "diagnostic", "neurology", "metabolic imaging" ;
  nuclide:modality "PET tracer" ;
  nuclide:approval "US 2004: FDG-PET nationally covered by Medicare specifically to differentiate Alzheimer's disease from frontotemporal dementia in patients with an uncertain diagnosis after comprehensive specialist evaluation (NCD 220.6.13)" ;
  nuclide:related <https://nuclide.cc/indications/alzheimers-disease/>, <https://nuclide.cc/drugs/fludeoxyglucose-f18/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/drugs/tc-99m-hmpao-brain/>, <https://nuclide.cc/isotopes/f-18/> .